Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | APP | P05067 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302869 | 0.86 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL3299202 | 0.86 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL3305487 | 0.84 | ALDH1A1 (0.45) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL21565858 | 0.78 | ALDH1A3 (0.46) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL3302417 | 0.75 | APP (0.56) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL3298658 | 0.74 | ALDH1A1 (0.65) | ALDH1A1NPC1RAB9AKDM4EGLA | |
| SCHEMBL3302355 | 0.73 | APP (0.57) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL21565920 | 0.71 | APP (0.56) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL1999354 | 0.70 | SMN1; SMN2 (0.61) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL21565860 | 0.70 | MAPT (0.57) | ALDH1A1NPC1RAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | claimed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| EP-2125800-A1 | NOVEL HETEROARYL SUBSTITUTED IMIDAZO Ý1,2 -A¨PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008091195-A1 | NOVEL HETEROARYL SUBSTITUTED IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008091195-A1 | NOVEL HETEROARYL SUBSTITUTED IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | APP, PSEN1, PSEN2 | ALDH1A1 1631/4885NPC1 189/4885RAB9A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.